Last reviewed · How we verify
CSL_112
CSL_112 is a recombinant human monoclonal antibody that targets the complement system.
CSL_112 is a recombinant human monoclonal antibody that targets the complement system. Used for Paroxysmal nocturnal hemoglobinuria (PNH).
At a glance
| Generic name | CSL_112 |
|---|---|
| Sponsor | CSL Behring |
| Drug class | Complement inhibitor |
| Target | C5 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
CSL_112 works by inhibiting the complement system, which is a part of the immune system that helps to clear pathogens from the body. By inhibiting the complement system, CSL_112 aims to reduce inflammation and prevent tissue damage.
Approved indications
- Paroxysmal nocturnal hemoglobinuria (PNH)
Common side effects
- Headache
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CSL_112 CI brief — competitive landscape report
- CSL_112 updates RSS · CI watch RSS
- CSL Behring portfolio CI